Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02342704 · ClinicalTrials.gov registry record · Phase 4
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
A Phase 4 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 4
- Development phase
- 111
- Enrollment target
NCT02342704 is a Phase 4 study that was terminated before completion, run by Biogen. The registered enrollment target is 111 participants.
The verdict
NCT02342704, a Phase 4 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 111 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the effect of natalizumab compared to fingolimod on the evolution of new on-treatment T1-gadolinium-enhancing (Gd+) lesions to persistent black holes (PBH) over 52 weeks. The secondary objectives of this study in this study population are to assess the effect of natalizumab compared to fingolimod on: magnetic resonance imaging (MRI) measures of central nervous system (CNS) tissue destruction as measured by the number of new T1-Gd+ lesions; various other MRI measures of disease activity; No Evidence of Disease Activity (NEDA); Relapse on treatment over 52 weeks; The change in information processing speed as measured by the Symbol Digit Modalities Test (SDMT).
Interventions
- DRUG natalizumab
- DRUG fingolimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2014-11-30 |
| Est. Completion | 2016-05-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02342704
The ClinicalTrials.gov registry entry for NCT02342704 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which natalizumab is the first listed.
NCT02342704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02342704 about?
NCT02342704 is a clinical study titled "Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants". The primary objective of this study is to assess the effect of natalizumab compared to fingolimod on the evolution of new on-treatment T1-gadolinium-enhancing (Gd+) lesions to persistent black holes (PBH) over 52 weeks. The secondary objectives of this study in this study population are to assess th...
What is the current status of trial NCT02342704?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 111 participants. The study started on 2014-11-30. Estimated completion is 2016-05-18.
What interventions are being tested in trial NCT02342704?
The interventions under investigation include: natalizumab (DRUG), fingolimod (DRUG).
Who is sponsoring clinical trial NCT02342704?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.